Document is current
Any future updates will be listed below
-
Authors
Zaleta, Alexandra K. https://orcid.org/0000-0002-8589-4722
Fortune, Erica E. https://orcid.org/0000-0002-6748-8229
Miller, Melissa F. https://orcid.org/0000-0001-8288-2681
Olson, Julie S. https://orcid.org/0000-0002-4669-3880
Hollis-Hansen, Kelseanna https://orcid.org/0000-0002-0243-2830
Dohn, Stacey Karpen
Kwait, Jennafer L. https://orcid.org/0000-0002-9490-0055
-
Funding
Funding for this research was provided by:
Gilead Sciences (Gilead Sciences)
- License Information
-
More Information
Article History
Accepted: 26 December 2023
First Online: 23 January 2024
Declarations
:
: The authors report the following. Institutional research support was granted to the Cancer Support Community and not individual study authors:Dr. Zaleta: Institutional research funding from: Astellas Pharma, Boston Scientific Foundation, Gilead Sciences, Novartis, Seattle Genetics; Institutional advisory funding from: BeiGene, Bristol Myers Squibb.Dr. Fortune: Institutional research funding from: AbbVie, Amgen Oncology, AstraZeneca, Astellas Pharma, Bristol Myers Squibb, Genentech, Gilead Sciences, Lilly Oncology, Merck, Sumitomo Dainippon Pharma Co, Takeda Oncology.Dr. Miller: Institutional research funding from: Astellas Pharma, BeiGene, Bristol Myers Squibb, Genentech (a member of the Roche Group), Geron, Gilead Sciences, GlaxoSmithKline, Janssen Oncology, Merck, Novartis, Pfizer, Seagen, Taiho Oncology, and Takeda Oncology.Dr. Olson: No disclosures.Dr. Hollis-Hansen: No disclosures.Dr. Karpen Dohn: No disclosures.Dr. Kwait: No disclosures.
